Key Takeaways
- S&P Global Ratings downgraded Senegal to 'CC', warning that a distressed debt exchange or default on foreign-currency commercial debt is "extremely likely" following a $2.2 billion IMF agreement.
- Novartis (NVS) announced its Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary cardiovascular endpoint, despite successfully reducing Lp(a) levels.
- Donald Trump pledged to deploy $400 million to $500 million from the MAGA Inc. Super PAC to support Republican candidates in the upcoming midterm elections.
- Bank of America (BAC) is set to redeem $2 billion in senior notes on September 15, 2026, as part of its ongoing debt management strategy.
- The FDA is intervening to prevent a supply gap in neonatal starter nutrition after the planned shutdown of two major manufacturing facilities.
Sovereign Debt and Global Economy
S&P Global Ratings lowered Senegal’s long-term foreign currency sovereign credit rating to 'CC' from 'CCC+', citing a high risk of default. The downgrade follows the government's announcement of a "debt treatment plan" under the G20 Common Framework, which aims to restructure foreign currency debt while attempting to exclude local currency obligations.
The restructuring is a condition for a $2.2 billion staff-level agreement with the IMF. Analysts believe foreign creditors will likely receive less than originally promised, as the country grapples with a debt burden estimated at 132% of GDP following the discovery of previously unreported liabilities.
In Brazil, the government's 2027 budget proposal includes an extraordinary pre-salt oil auction expected to generate $4.4 billion (22.4 billion reais). This revenue is critical for the administration's goal of achieving a primary surplus and stabilizing the national fiscal trajectory.
Healthcare and Pharmaceutical Developments
Novartis (NVS) and its partner Ionis Pharmaceuticals (IONS) reported that the Phase III Lp(a)HORIZON trial for pelacarsen did not achieve its primary goal of reducing major adverse cardiovascular events. While the drug successfully lowered Lipoprotein(a) levels, the reduction did not translate into a statistically significant clinical benefit for the study population.
Separately, a new study published in Pediatrics reveals that prescriptions for GLP-1 weight-loss drugs (such as Wegovy and Zepbound) for U.S. children under 12 have surged 310-fold since 2019. Although not yet FDA-approved for this age group, doctors are increasingly prescribing them off-label to treat severe childhood obesity.
The FDA is also monitoring a potential shortage of neonatal starter parenteral nutrition (PN). The agency is taking steps to safeguard the availability of these life-saving products after two facilities responsible for their production announced permanent shutdowns, raising alarms at children's hospitals nationwide.
Corporate Finance and Geopolitics
Bank of America (BAC) announced it will redeem $500 million in floating-rate and $1.5 billion in fixed/floating-rate senior notes on September 15, 2026. The notes, originally due in 2027, will be redeemed at 100% of their principal amount plus accrued interest, a move intended to optimize the bank's interest expenses.
In the Middle East, Israel launched retaliatory strikes in southern Lebanon after Hezbollah targeted Israeli troops with a drone. The IDF reported intercepting the drone within its security zone, while Lebanese officials stated that the subsequent strikes resulted in at least three deaths and over 20 injuries.
On the political front, Donald Trump has bowed to Republican pressure to open MAGA Inc.’s $400 million war chest. The former president indicated he would allocate nearly half a billion dollars to help the party retain control of Congress in the November midterms, marking a significant shift in his campaign spending strategy.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.